The study analysed that the Synovial sarcoma pipeline comprises of 22
drug candidates in different stages of development. Synovial sarcoma is rare
type of cancer and approximately one to three people in one million people are
diagnosed with synovial sarcoma every year, globally. The disease occurs
frequently in young adults; however, the disease can affect a person at any
age. Synovial sarcoma is more common in males, and the male to female ratio of
the disease stands at 12 males for every 10 females. Various new therapies and
advanced technologies are driving the growth of Synovial sarcoma pipeline.
Browse Report Description at: https://www.psmarketresearch.com/market-analysis/synovial-sarcoma-therapeutics-pipeline-analysis
Many technologies such as REOLYSIN technology, ZVex and GLAAS
technology, Laser Micro-beam Microdissection are being developed that can bring
the innovative treatment, which can control the progression of Synovial
sarcoma. ZVex and GLAAS are complementary discovery platforms designed to
activate and expand the immune system’s natural ability to create tumour-specific
cytotoxic T cells (CTLs) in vivo.
The research also found that various companies have collaborated for the
development of Synovial sarcoma pipeline. In February 2014, Pfizer Inc.
(Pfizer) and Merck & Co., Inc. (Merck) agreed to explore the therapeutic
potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination
with two of the Pfizer’s oncology assets.
Explore Report Sample
at: https://www.psmarketresearch.com/market-analysis/synovial-sarcoma-therapeutics-pipeline-analysis/report-sample
Some of the key players developing drugs for Synovial sarcoma include
Takara Bio Inc., Oncolytics Biotech Inc., Accuronix Therapeutics, Inc., Cue
Biopharma, Inc. and others.
No comments:
Post a Comment